CN101428024A - Lafutidine-containing medicament composition for treating peptic ulcer - Google Patents
Lafutidine-containing medicament composition for treating peptic ulcer Download PDFInfo
- Publication number
- CN101428024A CN101428024A CNA2008103049156A CN200810304915A CN101428024A CN 101428024 A CN101428024 A CN 101428024A CN A2008103049156 A CNA2008103049156 A CN A2008103049156A CN 200810304915 A CN200810304915 A CN 200810304915A CN 101428024 A CN101428024 A CN 101428024A
- Authority
- CN
- China
- Prior art keywords
- ulcer
- erythromycin
- gastric acid
- inhibitor
- acid secretion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- KMZQAVXSMUKBPD-DJWKRKHSSA-N Lafutidine Chemical compound C=1C=COC=1C[S+]([O-])CC(=O)NC\C=C/COC(N=CC=1)=CC=1CN1CCCCC1 KMZQAVXSMUKBPD-DJWKRKHSSA-N 0.000 title claims abstract description 22
- 229960003303 lafutidine Drugs 0.000 title claims abstract description 22
- 239000003814 drug Substances 0.000 title abstract description 33
- 208000008469 Peptic Ulcer Diseases 0.000 title abstract description 7
- 208000011906 peptic ulcer disease Diseases 0.000 title abstract description 7
- 230000027119 gastric acid secretion Effects 0.000 claims abstract description 35
- 239000003112 inhibitor Substances 0.000 claims abstract description 27
- 229930182555 Penicillin Natural products 0.000 claims abstract description 25
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims abstract description 25
- 229940049954 penicillin Drugs 0.000 claims abstract description 25
- 241000590002 Helicobacter pylori Species 0.000 claims abstract description 19
- 229940037467 helicobacter pylori Drugs 0.000 claims abstract description 19
- 208000007107 Stomach Ulcer Diseases 0.000 claims abstract description 18
- 201000005917 gastric ulcer Diseases 0.000 claims abstract description 17
- 239000003826 tablet Substances 0.000 claims abstract description 12
- 239000002775 capsule Substances 0.000 claims abstract description 8
- 239000008187 granular material Substances 0.000 claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 239000000829 suppository Substances 0.000 claims abstract description 4
- 239000006188 syrup Substances 0.000 claims abstract description 4
- 235000020357 syrup Nutrition 0.000 claims abstract description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 6
- 238000013270 controlled release Methods 0.000 claims description 5
- -1 electuary Substances 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000007943 implant Substances 0.000 claims description 2
- 239000004005 microsphere Substances 0.000 claims 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 abstract description 84
- 229960003276 erythromycin Drugs 0.000 abstract description 42
- 208000025865 Ulcer Diseases 0.000 abstract description 40
- 231100000397 ulcer Toxicity 0.000 abstract description 40
- 230000002401 inhibitory effect Effects 0.000 abstract description 32
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 abstract description 28
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 abstract description 27
- 229960000282 metronidazole Drugs 0.000 abstract description 27
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 abstract description 25
- 229960001625 furazolidone Drugs 0.000 abstract description 25
- 229960003022 amoxicillin Drugs 0.000 abstract description 18
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 abstract description 18
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 abstract description 18
- 239000004098 Tetracycline Substances 0.000 abstract description 17
- 229960002180 tetracycline Drugs 0.000 abstract description 17
- 229930101283 tetracycline Natural products 0.000 abstract description 17
- 235000019364 tetracycline Nutrition 0.000 abstract description 17
- 150000003522 tetracyclines Chemical class 0.000 abstract description 17
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 abstract description 16
- 229930182566 Gentamicin Natural products 0.000 abstract description 16
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 abstract description 16
- 102000004190 Enzymes Human genes 0.000 abstract description 9
- 108090000790 Enzymes Proteins 0.000 abstract description 9
- 239000007924 injection Substances 0.000 abstract description 9
- 238000002347 injection Methods 0.000 abstract description 9
- 102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 abstract description 8
- 108010083204 Proton Pumps Proteins 0.000 abstract description 8
- 229940069428 antacid Drugs 0.000 abstract description 8
- 239000003159 antacid agent Substances 0.000 abstract description 8
- 230000001458 anti-acid effect Effects 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 7
- 239000003405 delayed action preparation Substances 0.000 abstract description 3
- 239000000725 suspension Substances 0.000 abstract description 3
- 239000007938 effervescent tablet Substances 0.000 abstract description 2
- OVBICQMTCPFEBS-SATRDZAXSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[bi Chemical compound CC(O)=O.CC(O)=O.C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 OVBICQMTCPFEBS-SATRDZAXSA-N 0.000 abstract 1
- 102000000543 Histamine Receptors Human genes 0.000 abstract 1
- 108010002059 Histamine Receptors Proteins 0.000 abstract 1
- 108700032141 ganirelix Proteins 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
- 229960000381 omeprazole Drugs 0.000 description 29
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 24
- 229960003174 lansoprazole Drugs 0.000 description 22
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 21
- 229960001380 cimetidine Drugs 0.000 description 21
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 21
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 20
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 description 20
- ZBFDAUIVDSSISP-UHFFFAOYSA-N 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]-1H-imidazo[4,5-b]pyridine Chemical compound N=1C2=NC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C ZBFDAUIVDSSISP-UHFFFAOYSA-N 0.000 description 18
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 18
- 229960000620 ranitidine Drugs 0.000 description 18
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 18
- PSIREIZGKQBEEO-UHFFFAOYSA-N 2-(1h-benzimidazol-2-ylsulfinylmethyl)-n-methyl-n-(2-methylpropyl)aniline Chemical compound CC(C)CN(C)C1=CC=CC=C1CS(=O)C1=NC2=CC=CC=C2N1 PSIREIZGKQBEEO-UHFFFAOYSA-N 0.000 description 17
- 229960001596 famotidine Drugs 0.000 description 17
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 17
- 229950007395 leminoprazole Drugs 0.000 description 17
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 16
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 16
- 229960005019 pantoprazole Drugs 0.000 description 16
- 229960004157 rabeprazole Drugs 0.000 description 16
- 229950008375 tenatoprazole Drugs 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 229960000723 ampicillin Drugs 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 230000028327 secretion Effects 0.000 description 14
- 210000002784 stomach Anatomy 0.000 description 13
- SMTZFNFIKUPEJC-UHFFFAOYSA-N Roxane Chemical compound CC(=O)OCC(=O)NCCCOC1=CC=CC(CN2CCCCC2)=C1 SMTZFNFIKUPEJC-UHFFFAOYSA-N 0.000 description 12
- 229950002968 dosmalfate Drugs 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 12
- 229960003320 roxatidine Drugs 0.000 description 12
- RIIQJLBJDMMSSK-RHFFRRHRSA-A tetradecaaluminum;[2-methoxy-5-[7-[(2s,3r,4s,5r,6r)-6-[[(2r,3r,4r,5s,6s)-6-methyl-3,4,5-trisulfonatooxyoxan-2-yl]oxymethyl]-3,4,5-trisulfonatooxyoxan-2-yl]oxy-4-oxo-5-sulfonatooxychromen-2-yl]phenyl] sulfate;pentatriacontahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].C1=C(OS([O-])(=O)=O)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(OS([O-])(=O)=O)C=C2O[C@H]1[C@H](OS([O-])(=O)=O)[C@@H](OS([O-])(=O)=O)[C@H](OS([O-])(=O)=O)[C@@H](CO[C@H]2[C@@H]([C@H](OS([O-])(=O)=O)[C@@H](OS([O-])(=O)=O)[C@H](C)O2)OS([O-])(=O)=O)O1 RIIQJLBJDMMSSK-RHFFRRHRSA-A 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 210000004211 gastric acid Anatomy 0.000 description 11
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 10
- 150000003851 azoles Chemical class 0.000 description 10
- 229910000019 calcium carbonate Inorganic materials 0.000 description 10
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 10
- 239000000347 magnesium hydroxide Substances 0.000 description 10
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 10
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 10
- 235000017557 sodium bicarbonate Nutrition 0.000 description 10
- GFWRVVCDTLRWPK-KPKJPENVSA-N sofalcone Chemical compound C1=CC(OCC=C(C)C)=CC=C1\C=C\C(=O)C1=CC=C(OCC=C(C)C)C=C1OCC(O)=O GFWRVVCDTLRWPK-KPKJPENVSA-N 0.000 description 10
- 229950004782 sofalcone Drugs 0.000 description 10
- 229940122236 Histamine receptor antagonist Drugs 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 230000001629 suppression Effects 0.000 description 9
- 239000000739 antihistaminic agent Substances 0.000 description 8
- 208000000718 duodenal ulcer Diseases 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 230000001079 digestive effect Effects 0.000 description 7
- 210000002249 digestive system Anatomy 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000002156 mixing Methods 0.000 description 6
- 229940126409 proton pump inhibitor Drugs 0.000 description 6
- 239000000612 proton pump inhibitor Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010019375 Helicobacter infections Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 229960001340 histamine Drugs 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000007779 soft material Substances 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 210000001711 oxyntic cell Anatomy 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004051 gastric juice Anatomy 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 229940121819 ATPase inhibitor Drugs 0.000 description 2
- 240000006891 Artemisia vulgaris Species 0.000 description 2
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 2
- 102100021022 Gastrin Human genes 0.000 description 2
- 108010052343 Gastrins Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 229940062327 aciphex Drugs 0.000 description 2
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 description 2
- 210000002318 cardia Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 206010013864 duodenitis Diseases 0.000 description 2
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 description 2
- 229960004770 esomeprazole Drugs 0.000 description 2
- KWORUUGOSLYAGD-YPPDDXJESA-N esomeprazole magnesium Chemical compound [Mg+2].C([S@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C.C([S@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C KWORUUGOSLYAGD-YPPDDXJESA-N 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229940112641 nexium Drugs 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 229940100691 oral capsule Drugs 0.000 description 2
- 208000000689 peptic esophagitis Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- 229940023488 pill Drugs 0.000 description 2
- 229940032668 prevacid Drugs 0.000 description 2
- 229940089505 prilosec Drugs 0.000 description 2
- 229940061276 protonix Drugs 0.000 description 2
- KRCQSTCYZUOBHN-UHFFFAOYSA-N rabeprazole sodium Chemical compound [Na+].COCCCOC1=CC=NC(CS(=O)C=2[N-]C3=CC=CC=C3N=2)=C1C KRCQSTCYZUOBHN-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 208000002310 Achlorhydria Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- 206010060377 Hypergastrinaemia Diseases 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- 210000002255 anal canal Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 210000003890 endocrine cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical group C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000004203 pyloric antrum Anatomy 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000005245 right atrium Anatomy 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 210000005090 tracheal smooth muscle Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to pharmaceutical composition containing lafutidine for treating peptic ulcer. The pharmaceutical composition is characterized in that the composition comprises the following components: at least a helicobacter pylori inhibitor and at least a gastric acid secretion inhibitor. The helicobacter pylori inhibitor is selected from penicillin, penbritin, amoxicillin, metronidazole, furazolidone, erythromycin, erythromycin and the analog thereof, gentamycin and tetracycline, and the gastric acid secretion inhibitor comprises histamine receptor antagon, H<+>/K<+>-ATP enzyme (proton pump) and/or antacid. The composition can be produced into granules, effervescent tablets, tablets, capsules, syrup, injection, suspension injection, suppositories or sustained/controlled-release preparation, oral medicines or non-oral medicines, and can achieve the purpose of preventing and treating gastric ulcer and doudenal ulcer by effectively inhibiting the growth of helicobacter pylori and gastric acid secretion.
Description
Technical field
The present invention relates to a kind of treatment digestive ulcer medicament compositions, belong to medical technical field.
The research background
Peptic ulcer mainly refers to gastric ulcer and duodenal ulcer, and pathological changes is confined to stomach and 12 and refers to mucosa.Along with the Chinese society development, the change of circumstances, the variation of population structure and people life style, main because of smoking, drink, peptic ulcer rate that nervous, medicine irritation etc. causes increases gradually, become a kind of commonly encountered diseases and frequently-occurring disease, bring great misery to the patient, cause patients ' life quality to descend.Therefore for these reasons, the treatment of peptic ulcer more and more receives publicity clinically and payes attention to, and invents a kind of medicament for resisting peptic ulcer safely and effectively to have received very big concern, and becomes one of the emphasis of present drug development research and focus.
Think always that for many years gastric ulcer and duodenal ulcer are main because due to the gastric acid excessive secretion.So mainly be the gastric acid inhibitory secretion aspect treatment.It is a lot of to secrete the medicine for the treatment of digestive system and ulcer by gastric acid inhibitory at present, comprises histamine receptor antagonist, antacid and H
+-K
+ATP enzyme (claiming proton pump again) inhibitor etc.Wherein, histamine receptor antagonist as, but be not limited to cimetidine (cimetidine), ranitidine (ranitidine), lafutidine (lafutidine), famotidine (famotidine) and roxatidine (roxatidine) etc.; And H
+-K
+ATP enzyme (claiming proton pump again) inhibitor comprises rabeprazole (rabeprazole, E-3810, LY307640, Aciphex), Tenatoprazole (tenatoprazole, TU-199), omeprazole (Omeprazole, Prilosec), lansoprazole (lansoprazole, AG-1749, Prevacid), pantoprazole (pantoprazole, Protonix), S-omeprazole (esomeprazole, Nexium), Lan Minuola azoles (leminoprazole), tenooprazole (tenooprazole), rabmprazole (rabmprazole), leminoprazole, dosmalfate (dosmalfate) and sofalcone etc.; Antacid as, but be not limited to aluminium hydroxide, magnesium hydroxide, sodium bicarbonate and calcium carbonate etc.
Histamine receptor antagonist can be secreted by gastric acid inhibitory, though it is stronger the influence of gastric acid secretion to be compared the influence of other physiological function, but because histamine's receptor also is present in many other tissues, comprise blood vessel, tracheal smooth muscle and right atrium etc., so such medicine has than significant side effects to circulation, breathing and central nervous system.Not ideal enough as cimetidine and ranitidine treatment peptic ulcer effect.Cause ulcer recurrence easily.H
+/ K
+-atpase inhibitor, promptly proton pump inhibitor (PPI) is the excretory medicine of the novel gastric acid inhibitory of a class.The excretory effect of this type of medicine gastric acid inhibitory is stronger, but stable inadequately under sour environment, and therefore, therapeutic effect is difficult to consolidate.In addition, proton pump inhibitor such as omeprazole also can cause hypergastrinemia (Arnold R et al., 1986 by starting the gastric antrum feedback mechanism; Creutzfeldt W et al., 198; Larsson H., 1986), cause the diffusivity endocrine cell hyperplasia of body of stomach then, be carcinoid feature (Ekan et al., 1985)--achlorhydria.Thereby the long-term H that uses separately
+/ K
+-atpase inhibitor is very limited, and dosage is not enough or treat and irregularly will cause ulcer repeatedly.
Up-to-date discovers, gastric acid secretion is a complex physical process, and wherein, histamine, gastrin and acetylcholine etc. can stimulate the activity of parietal cell, gastrin and acetylcholine except direct effect, also can promote gastric mucosal cell to discharge the histamine that stores to parietal cell.Therefore, histamine is the important mediation person of gastric acid secretion.Another important step that causes gastric acid secretion is the commentaries on classics shape that occurs in the film on the parietal cell.After cell was stimulated, intracellular pipe capsule melted to be incorporated on the plasma membrane of top and forms an expansible secretory tubyle, and H is wherein arranged
+/ K
+-ATP enzyme.By this mode, H
+/ K
+-ATP enzyme (proton pump) is with H
+With K
+Exchange finally mediates gastric acid secretion.Therefore, histamine is the important mediation person of gastric acid secretion, and is positioned at the tubulovesicle of parietal cell and secretes H on the periosteum
+/ K
+-ATP enzyme (proton pump) participates in last link of gastric acid secretion.Simple one of them link that suppresses has certain inhibitory action to gastric acid secretion, but DeGrain.Increased dosage amount will be subjected to the restriction of toxic reaction, and dosage is not enough or treat and irregularly will cause disease relapse.
Moreover, up-to-date discovers, the gastric acid excessive secretion is not the main cause of ulcer, and wherein helicobacter pylori infection is being brought into play more and more important effect in gastric ulcer and duodenal ulcer form.The two mutually promotes helicobacter pylori infection and gastric acid excessive secretion, therefore, for a long time, secretes by gastric acid inhibitory merely and treats gastric ulcer and the duodenal ulcer effect is not very good.In addition, helicobacter pylori infection and gastric cancer has a confidential relation.Not only can effectively treat gastric ulcer and duodenal ulcer so effectively suppress helicobacter pylori infection, important function is taken place to have equally prevention gastric cancer.
Summary of the invention
The present invention is directed to the deficiencies in the prior art a kind of treatment digestive system and ulcer pharmaceutical composition is provided, this medicine is treated digestive system and ulcer by effective inhibition helicobacter pylori infection and the secretion of effective gastric acid inhibitory.
The present invention treats the digestive ulcer medicament compositions, comprises the helicobacter pylori inhibitor of effective dose and the gastric acid secretion inhibitor of effective dose.Reach the purpose for the treatment of digestive system and ulcer effectively by effective gastric acid inhibitory secretion and effective helicobacter pylori that suppresses.
The helicobacter pylori inhibitor mainly comprises the antibiotic that can eliminate helicobacter pylori (gastric ulcer pathogenic bacterium) in the compositions of the present invention, as, but be not limited to, penicillin, ampicillin, amoxicillin (amoxicillin, amoxicillin), metronidazole, furazolidone, erythromycin (Erythromycin), erythromycin (clarithromycin) and analog, gentamycin and tetracycline (tetracycline) etc.
The present invention treats that gastric acid secretion inhibitor comprises histamine receptor antagonist and/or H in the digestive ulcer medicament compositions
+-K
+ATP enzyme (claiming proton pump again) inhibitor and/or antacid etc.
Wherein, histamine receptor antagonist comprise for class D chemical compound or medicine as, but be not limited to cimetidine (cimetidine), ranitidine (ranitidine), lafutidine (lafutidine), famotidine (famotidine) and roxatidine (roxatidine) etc.; And H
+-K
+ATP enzyme (claiming proton pump again) inhibitor comprise Omprazole compound or medicine as, but be not limited to, rabeprazole (rabeprazole, E-3810, LY307640, Aciphex), Tenatoprazole (tenatoprazole, TU-199), omeprazole (Omeprazole, Prilosec), lansoprazole (lansoprazole, AG-1749, Prevacid), pantoprazole (pantoprazole, Protonix), S-omeprazole (esomeprazole, Nexium), Lan Minuola azoles (leminoprazole), tenooprazole (tenooprazole), rabmprazole (rabmprazole), leminoprazole, dosmalfate (dosmalfate) and sofalcone etc.; Antacid includes, but not limited to aluminium hydroxide, magnesium hydroxide, sodium bicarbonate and calcium carbonate etc.
The present invention treats that helicobacter pylori inhibitor and gastric acid secretion inhibitor weight ratio are (1-100) in the digestive ulcer medicament compositions: (100-1).
The present invention treats the digestive ulcer medicament compositions can contain at least a helicobacter pylori inhibitor and at least a gastric acid secretion inhibitor.Wherein preferred compositions comprises:
1) combination of 1-30% penicillin, ampicillin, amoxicillin, metronidazole, furazolidone, erythromycin, erythromycin, gentamycin or tetracycline and 1-30% cimetidine, ranitidine, lafutidine, famotidine or roxatidine; Or
2) combination of 1-30% penicillin, ampicillin, amoxicillin, metronidazole, furazolidone, erythromycin, erythromycin, gentamycin or tetracycline and 1-30% lansoprazole, omeprazole, rabeprazole, Tenatoprazole, pantoprazole, S-omeprazole, Lan Minuola azoles, tenooprazole, rabmprazole, leminoprazole, dosmalfate or sofalcone; Or
3) combination of 1-30% penicillin, ampicillin, amoxicillin, metronidazole, furazolidone, erythromycin, erythromycin, gentamycin or tetracycline and 1-30% aluminium hydroxide, magnesium hydroxide, sodium bicarbonate or calcium carbonate; Or
4) combination of 5% penicillin, ampicillin, amoxicillin, metronidazole, furazolidone, erythromycin, erythromycin, gentamycin or tetracycline and 80% cimetidine, ranitidine, lafutidine, famotidine or roxatidine and 15% lansoprazole, omeprazole, rabeprazole, Tenatoprazole, pantoprazole, S-omeprazole, Lan Minuola azoles, tenooprazole, rabmprazole, leminoprazole, dosmalfate or sofalcone; Or
5) combination of 5% penicillin, ampicillin, amoxicillin, metronidazole, furazolidone, erythromycin, erythromycin, gentamycin or tetracycline and 80% cimetidine, ranitidine, lafutidine, famotidine or roxatidine and 15% aluminium hydroxide, magnesium hydroxide, sodium bicarbonate or calcium carbonate; Or
6) 5% penicillin, ampicillin, amoxicillin, metronidazole, furazolidone, erythromycin, erythromycin, gentamycin or tetracycline and with the combination of 15% lansoprazole, omeprazole, rabeprazole, Tenatoprazole, pantoprazole, S-omeprazole, Lan Minuola azoles, tenooprazole, rabmprazole, leminoprazole, dosmalfate or sofalcone and 15% aluminium hydroxide, magnesium hydroxide, sodium bicarbonate or calcium carbonate; Or
7) 5% penicillin, ampicillin, amoxicillin, metronidazole, furazolidone, erythromycin, erythromycin, gentamycin or tetracycline and 65% cimetidine, ranitidine, lafutidine, famotidine or roxatidine and 15% lansoprazole, omeprazole, rabeprazole, Tenatoprazole, pantoprazole, S-omeprazole, the Lan Minuola azoles, tenooprazole, rabmprazole, leminoprazole, dosmalfate or sofalcone and 15% aluminium hydroxide, magnesium hydroxide, the combination of sodium bicarbonate or calcium carbonate.
The preferred compositions that the present invention treats the digestive ulcer medicament compositions also comprises:
1) combination of a kind of helicobacter pylori inhibitor and a kind of histamine receptor antagonist and a kind of proton pump inhibitor;
2) combination of a kind of helicobacter pylori inhibitor and a kind of histamine receptor antagonist and a kind of antacid;
3) combination of a kind of helicobacter pylori inhibitor and a kind of proton pump inhibitor and a kind of antacid;
4) combination of a kind of helicobacter pylori inhibitor, a kind of histamine receptor antagonist, a kind of proton pump inhibitor and a kind of antacid.
The present invention treats the digestive system and ulcer compositions, and to be used for the treatment of the gastric and duodenal ulcers side effect little, the safe coefficient height.Effective ingredient can directly be taken raw material in the compositions, but uses after preferably its effective ingredient being made various pharmaceutical dosage forms.Effective ingredient and pharmaceutical carrier and excipient and/or carrier holder can be mixed, make various oral formulations or non-intestinal application forms.Oral agents can be, but is not limited to, powder, granule, tablet, pill, capsule, electuary, powder, syrup, slow releasing agent, controlled release agent or slowbreak agent.The dosage of every day is 0.01 to 50 milligram of everyone 1 to 5000 milligram or per kilogram of body weight when oral, and the dosage of every day is 0.1 to 2.5 milligram of everyone 10 to 250 milligrams or per kilogram of body weight preferably.Wherein the ratio of helicobacter pylori inhibitor and gastric acid secretion inhibitor is decided because of concrete condition, can be by non-intestinal application forms from 1:10 to 10:1., but be not limited to injection, suppository or implant.By 0.5 to the 10% w/v injection of making soluble in water, the suitable dose of injection is 0.5 to 5000 milligram for each person every day with water solublity active drug composition, with for each person every day 100 to 500 milligrams be the best.The dosage of every day can once be taken or be divided into 2 to 4 times and take.Also the active drug composition can be wrapped in and make agent for slow releasing in the slow-release auxiliary material, agent for slow releasing can be slow releasing agent, controlled release agent or slowbreak agent, can be oral or through subcutaneous or intramuscular injection or place in anal canal, as suppository.
The present invention treat the effective ingredient of digestive system and ulcer compositions can medicine and/or the mode of nutrient and healthcare products use.Wherein best form is with its effective ingredient rapid release at gastric.The effective ingredient of compositions can be made powder, granule, tablet (coated tablet, effervescent tablet, slow releasing tablet), pill, capsule, electuary, powder, syrup, slow releasing agent, controlled release agent, slowbreak agent, suspension or injection separately or with pharmaceutical carrier, excipient.For the effective ingredient that can make compositions plays a role at the multiple position of ulcer (as stomach and duodenum), the effective ingredient of compositions is preferably made lamellar, capsule, injection, suspension or slow releasing agent.
Effective ingredient of the present invention can be made various dosage forms through traditional preparation process.When making solid oral dosage form, effective ingredient is mixed with filler, add binding agent, disintegrating agent, lubricant, developer, corrigent or its analog in case of necessity, then mixture is made tablet or capsule.Following preparation method and non-active ingredient just are used for further specifying of the present invention, are not limitation of the present invention.Equally, the used effective ingredient of the present invention with and application etc. just be used for further specifying to of the present invention, be not limitation of the present invention.
Compositions of the present invention mainly by effective inhibition helicobacter pylori and gastric acid secretion be used for the treatment of gastric ulcer, duodenal ulcer, reflux esophagitis, Zhuo-Chinese mugwort syndrome etc., stomach and duodenitis and with gastric acid secretion imbalance diseases associated.Therefore the main component of the present composition be used for preparation treatment treatment gastric ulcer, duodenal ulcer, reflux esophagitis, Zhuo-Chinese mugwort syndrome etc., stomach and duodenitis and with the lack of proper care pharmaceutical preparation of diseases associated of gastric acid secretion.
Compositions of the present invention is with the inhibition of application helicobacter pylori, histamine H 2-receptor antagonist or proton pump inhibitor are compared separately, has obvious superiority,, good effect wide as the range of choice, few side effects, effect stability do not recur, and its superiority can be embodied by following experimental result.
1, to the influence of gastric acid secretion:
Treating excess syndrome is tested with female, 6 weeks, body weight 150-170 gram Wistar rat, and single being fixed in makes its fasting can't help water 48 hours in the ferrum cage.Take medicine and after 1 hour its stomachus pyloricus (stomach lower end) is used the surgical thread ligation.Rat was put to death with CO2 in 19 hours after the ligation.With stomach cardia portion (Weishang end) ligation, purpose is to prevent that gastric juice from flowing out with surgical thread in the dissection back.And then stomach taken off, the place cuts off stomach along greater gastric curvature, makes gastric juice flow into centrifuge tube, adds 40ml distilled water and 3 (10mg/ml) phenolphthalein behind the centrifugal 40min of 2400 commentaries on classics/min again.Use 0.1mol/L NaOH titration afterwards.Write down the volume of the NaOH that consumes, and calculate inhibitory action as follows gastric acid secretion.
Press down sour rate=[(blank animal NaOH consumes volume medication animal NaOH and consumes volume)/blank animal NaOH consumes volume] * 100%
2, the inhibitory action of ulcer
Make its fasting can't help water 48 hours in the ferrum cage single being fixed in of same experimental rat.Take medicine and after 1 hour its stomachus pyloricus (stomach lower end) is used the surgical thread ligation.Rat was used CO in 19 hours after the ligation
2Put to death.With stomach cardia portion (Weishang end) ligation, purpose is to prevent that gastric juice from flowing out with surgical thread in the dissection back.And then stomach taken off, the place cuts off stomach along greater gastric curvature, and water with the naked eye and in conjunction with anatomic microscope is observed the damaged surfaces degree after washing away the impurity on Weishang, and calculates ulcer index (UI) as follows, and ulcer inhibition rate.
Ulcer inhibition rate=[(matched group UI-medication group UI)/blank group UI] * 100%
Test one, compare metronidazole, lansoprazole, cimetidine and aluminium hydroxide inhibitory action rat tolerance secretion and ulcer.Experimental result (seeing Table one) shows, when above medicine is used separately gastric acid secretion all had in various degree inhibitory action, with lansoprazole and cimetidine to make effect best.When share, the inhibitory action of gastric acid secretion is not had obvious enhancing, but the inhibitory action of gastric ulcer is increased to some extent, best with the combined effect of metronidazole and lansoprazole or cimetidine.
Test two, compare erythromycin, omeprazole, rabeprazole and ranitidine inhibitory action rat tolerance secretion and ulcer.Experimental result (seeing Table two) shows, when above medicine is used separately gastric acid secretion all had in various degree inhibitory action.When share, the inhibitory action of gastric acid secretion is not had obvious enhancing, but the inhibitory action of gastric ulcer is increased to some extent.
Test three, compare penicillin, Tenatoprazole, pantoprazole and lafutidine inhibitory action rat tolerance secretion and ulcer.Experimental result (seeing Table three) shows, when above medicine is used separately gastric acid secretion all had in various degree inhibitory action.When share, the inhibitory action of gastric acid secretion is not had obvious enhancing, but the inhibitory action of gastric ulcer is increased to some extent.
Test four, compare furazolidone, tenooprazole, leminoprazole and famotidine inhibitory action rat tolerance secretion and ulcer.Experimental result (seeing Table four) shows, when above medicine is used separately gastric acid secretion all had in various degree inhibitory action.When share, the inhibitory action of gastric acid secretion is not had obvious enhancing, but the inhibitory action of gastric ulcer is increased to some extent.
Table one, metronidazole etc. are to the inhibitory action of rat tolerance secretion and ulcer
| Metronidazole (5mg) | Lansoprazole (7.5mg) | Cimetidine (25mg) | Aluminium hydroxide (7.5mg) | Gastric acid secretion suppression ratio (%) | Ulcer index | Ulcer suppression ratio (%) |
| - | - | - | - | 30 | ||
| + | - | - | - | 10 | 12 | 39 |
| - | + | - | - | 18 | 16 | 37 |
| - | - | + | - | 32 | 20 | 29 |
| - | - | - | + | 12 | 18 | 36 |
| + | + | - | - | 38 | 2.8 | 80 |
| + | - | + | - | 50 | 1.2 | 86 |
| + | - | - | + | 28 | 2 | 90 |
Table two, erythromycin etc. are to the inhibitory action of rat tolerance secretion and ulcer
| Erythromycin (100,000 unit) | Omeprazole (7.5mg) | Rabeprazole (7.5mg) | Ranitidine (25mg) | Gastric acid secretion suppression ratio (%) | Ulcer index | Ulcer suppression ratio (%) |
| - | - | - | - | 26 | ||
| + | - | - | - | 23 | 13 | 91 |
| - | + | - | - | 13 | 30 | 17 |
| - | - | + | - | 16 | 26 | 28 |
| - | - | - | + | 18 | 24 | 33 |
| + | + | - | - | 58 | 1.8 | 93 |
| + | - | + | - | 56 | 1.6 | 96 |
| + | - | - | + | 68 | 1.5 | 94 |
Table three, penicillin etc. are to the inhibitory action of rat tolerance secretion and ulcer
| Penicillin (7.5mg) | Tenatoprazole (15mg) | Pantoprazole (15mg) | Lafutidine (50mg) | Gastric acid secretion suppression ratio (%) | Ulcer index | Ulcer suppression ratio (%) |
| - | - | - | - | 28 | ||
| + | - | - | - | 32 | 12 | 27 |
| - | + | - | - | 12 | 22 | 24 |
| - | - | + | - | 13 | 28 | 28 |
| - | - | - | + | 16 | 20 | 29 |
| + | + | - | - | 62 | 1.4 | 95 |
| + | - | + | - | 54 | 1.2 | 92 |
| + | - | - | + | 58 | 1.8 | 90 |
Table four, furazolidone etc. are to the inhibitory action of rat tolerance secretion and ulcer
| Furazolidone (5mg) | Tenooprazole (10mg) | Leminoprazole (10mg) | Famotidine (50mg) | Gastric acid secretion suppression ratio (%) | Ulcer index | Ulcer suppression ratio (%) |
| - | - | - | - | 26 | ||
| + | - | - | - | 12 | 12 | 54 |
| - | + | - | - | 31 | 15 | 42 |
| - | - | + | - | 28 | 13 | 50 |
| - | - | - | + | 26 | 16 | 38 |
| + | + | - | - | 50 | 2 | 90 |
| + | - | + | - | 42 | 1.8 | 90 |
| + | - | - | + | 47 | 1.9 | 92 |
Test one shows to test four results: H
+-K
+ATP enzyme (claiming proton pump again) inhibitor and histamine receptor antagonists all have than the obvious suppression effect gastric acid secretion and ulcer, and when with helicobacter pylori inhibitor use in conjunction, its action effect is used more separately obviously and strengthened.Therefore, the helicobacter pylori inhibitor also may play a role by other mechanism.It should be noted that the dosage that is tried less (draw azole drug only for clinical consumption 1/10th to 1/5th, for the class D medicine only be clinical consumption 1/20th to 1/7th), its side effect or toxic reaction will obviously reduce during clinical practice.Safer, effective, convenient than original medicine, thus better choice provided for effectively treating digestive system and ulcer.
The specific embodiment
Embodiment 1, tablet, and preparation method thereof
Composition weight (mg)
1. active component 100
Wherein, active component is metronidazole 10 and lansoprazole 90
2. microcrystalline Cellulose 45
3. pregelatinized Starch 43
④Na
2HPO
4 2
5. cross-linked pvp 4.5
6. PVPK
3010% aqueous solution QS
7. cross-linked pvp 4.0
8. magnesium stearate 1.5
The preparation manipulation process:
(1) will 2. 3. 4. 5. accurately take by weighing respectively, cross 100 mesh sieves 2 times, fully mixing.
(2) take by weighing again 1. according to the equivalent method of progressively increasing, add in 1 step common mixing.
(3) drip an amount of 6. 10%PVPK
30Aqueous solution is made suitable soft material, makes wet granular by nylon mesh.
(4) soft material is put into drying baker in 40 ℃ of oven dry, temperature control 12 hours.
(5) again 7. 8. add in the dried granule, mixing, tabletting, make the 200mg tablet.
Embodiment 2,
As described in embodiment 1, different is that active component is:
1) 5mg metronidazole and 95mg cimetidine; Or
2) 20mg metronidazole and 80mg aluminium hydroxide; Or
3) 5mg metronidazole, 25mg lansoprazole and 70mg cimetidine; Or
4) 5mg metronidazole, 25mg lansoprazole and 70mg aluminium hydroxide; Or
5) 5mg metronidazole, 70mg cimetidine and 25mg aluminium hydroxide;
6) 5mg metronidazole, 15mg lansoprazole 60mg cimetidine and 20mg aluminium hydroxide.
Embodiment 3,
As described in embodiment 1, different is that active component is:
1) 35mg erythromycin and 65mg omeprazole; Or
2) 35mg erythromycin and 65mg rabeprazole; Or
3) 15mg erythromycin and 65mg ranitidine; Or
4) 5mg erythromycin, 25mg omeprazole and 70mg ranitidine; Or
5) 5mg erythromycin, 25mg rabeprazole and 70mg ranitidine
Embodiment 4,
As described in embodiment 1, different is that active component is:
1) 35mg penicillin and 65mg Tenatoprazole; Or
2) 35mg penicillin and 65mg pantoprazole; Or
3) 15mg penicillin and 65mg lafutidine; Or
4) 5mg penicillin, 25mg Tenatoprazole and 70mg lafutidine; Or
5) 5mg penicillin, 25mg pantoprazole and 70mg lafutidine
Embodiment 5,
As described in embodiment 1, different is that active component is:
Furazolidone, tenooprazole, leminoprazole and famotidine
1) 35mg furazolidone and 65mg tenooprazole; Or
2) 35mg furazolidone and 65mg leminoprazole; Or
3) 15mg furazolidone and 65mg famotidine; Or
4) 5mg furazolidone, 25mg tenooprazole and 70mg lafutidine; Or
5) 5mg furazolidone, 25mg leminoprazole and 70mg famotidine
Embodiment 6,
As described in embodiment 1, different is that active component is:
1) combination of 10% penicillin, ampicillin, amoxicillin, metronidazole, furazolidone, erythromycin, erythromycin, gentamycin or tetracycline and 90% cimetidine, ranitidine, lafutidine, famotidine or roxatidine; Or
2) combination of 20% penicillin, ampicillin, amoxicillin, metronidazole, furazolidone, erythromycin, erythromycin, gentamycin or tetracycline and 80% lansoprazole, omeprazole, rabeprazole, Tenatoprazole, pantoprazole, S-omeprazole, Lan Minuola azoles, tenooprazole, rabmprazole, leminoprazole, dosmalfate or sofalcone; Or
3) combination of 15% penicillin, ampicillin, amoxicillin, metronidazole, furazolidone, erythromycin, erythromycin, gentamycin or tetracycline and 85% aluminium hydroxide, magnesium hydroxide, sodium bicarbonate or calcium carbonate; Or
4) combination of 5% penicillin, ampicillin, amoxicillin, metronidazole, furazolidone, erythromycin, erythromycin, gentamycin or tetracycline and 80% cimetidine, ranitidine, lafutidine, famotidine or roxatidine and 15% lansoprazole, omeprazole, rabeprazole, Tenatoprazole, pantoprazole, S-omeprazole, Lan Minuola azoles, tenooprazole, rabmprazole, leminoprazole, dosmalfate or sofalcone; Or
5) combination of 5% penicillin, ampicillin, amoxicillin, metronidazole, furazolidone, erythromycin, erythromycin, gentamycin or tetracycline and 80% cimetidine, ranitidine, lafutidine, famotidine or roxatidine and 15% aluminium hydroxide, magnesium hydroxide, sodium bicarbonate or calcium carbonate; Or
6) 5% penicillin, ampicillin, amoxicillin, metronidazole, furazolidone, erythromycin, erythromycin, gentamycin or tetracycline and with the combination of 15% lansoprazole, omeprazole, rabeprazole, Tenatoprazole, pantoprazole, S-omeprazole, Lan Minuola azoles, tenooprazole, rabmprazole, leminoprazole, dosmalfate or sofalcone and 15% aluminium hydroxide, magnesium hydroxide, sodium bicarbonate or calcium carbonate; Or
7) 5% penicillin, ampicillin, amoxicillin, metronidazole, furazolidone, erythromycin, erythromycin, gentamycin or tetracycline and 65% cimetidine, ranitidine, lafutidine, famotidine or roxatidine and 15% lansoprazole, omeprazole, rabeprazole, Tenatoprazole, pantoprazole, S-omeprazole, the Lan Minuola azoles, tenooprazole, rabmprazole, leminoprazole, dosmalfate or sofalcone and 15% aluminium hydroxide, magnesium hydroxide, the combination of sodium bicarbonate or calcium carbonate.
Embodiment 7,150mg tablet
Composition weight (milligram)
Active component 45
Lactose 49.2
Starch 30
PVP 6
Microcrystalline Cellulose 18
Colloid silicon 1.2
Magnesium stearate 0.6
Total amount 150
Above-mentioned active component is respectively the combination among the embodiment 1-6.
The feasible where necessary Cotton seeds of tablet that the foregoing description 1-7 is made and granule is as sugar coating or gelatin etc.
The preparation of embodiment 8, enteric coatel tablets
1000 consumptions of composition monolithic consumption (mg) (g)
Label: 1. active component 100100
Wherein, active component is erythromycin 35 and omeprazole 65
2. microcrystalline Cellulose 54.5 54.5
3. pregelatinized Starch 34.5 34.5
④Na
2HPO
4 1.4 1.4
5. cross-linked pvp 4.6 4.6
6. PVPK
3010% aqueous solution QS QS
7. cross-linked pvp 4.0 4.0
8. magnesium stearate 1.0 1.0
Sealing coat: EH SL-S type
Enteric coating: EH ES-C type
The preparation manipulation process:
2. 3. 4. 5. accurately take by weighing respectively, cross 100 mesh sieves 2 times, fully mixing.
Take by weighing again 1. according to the equivalent method of progressively increasing, add in 1 step common mixing.
Drip an amount of 6. PVPK
3010% aqueous solution is made suitable soft material, makes wet granular by nylon mesh.
Soft material is put into drying baker in 40 ℃ of oven dry, temperature control 12 hours.
Again 7. 8. add in the dried granule, mixing, tabletting, coating.
Embodiment 9 is as described in the embodiment 8, and different is that active component is the combination among the embodiment 1-6.
The preparation of embodiment 10, oral capsule
Amounts of components (mg)
Active component 100
Wherein active component is oxytetracycline 35 and omeprazole 65
Lactose 100
Pregelatinized Starch 25
TC-5 20
Magnesium stearate 5
Total amount 150
(1) accurately takes by weighing above active ingredient and other adjuvant respectively, mix the back and dissolve with sodium hydrogen phosphate.
(2) using fluid bed drying after the soft material extrusion molding.
(3) granule of drying incapsulates.
The preparation method of oral capsule also can be made the capsule that contains the active ingredient of 50-100 milligram by other known technologies, makes the dosage form that 150-250mg does not wait.
Embodiment 11 is as described in the embodiment 10, and different is that active component is the combination among the embodiment 1-6.
Injection can be made through traditional method.Effective ingredient of the present invention is mixed with pH regulator agent, buffer, stabilizing agent, solvent and analog thereof etc., make injection then according to a conventional method and be used for subcutaneous, muscle and intravenous fluid.Sustained-release preparation can be made through traditional method, and also slow-release auxiliary material such as available high molecular polymer is that holder is made various dosage forms.
Claims (3)
- [claim 1] a kind of treatment gastric ulcer pharmaceutical composition is characterized in that said composition contains the helicobacter pylori inhibitor of effective dose and the gastric acid secretion inhibitor of effective dose,Described treatment gastric ulcer pharmaceutical composition is following combination:10% penicillin and 90% lafutidine;More than be weight percentage.
- [claim 2] treatment gastric ulcer as claimed in claim 1 pharmaceutical composition is characterized in that compositions is an oral formulations, is selected from powder, granule, tablet, pill, capsule, electuary, powder, syrup, slow releasing agent, controlled release agent or slowbreak agent.
- [claim 3] treatment gastric ulcer as claimed in claim 1 pharmaceutical composition is characterized in that said composition is a non-oral formulation, is selected from suspensoid injectio, suppository, injectable microsphere, implant, slow releasing agent, controlled release agent or slowbreak agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008103049156A CN101428024A (en) | 2005-11-09 | 2005-11-09 | Lafutidine-containing medicament composition for treating peptic ulcer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008103049156A CN101428024A (en) | 2005-11-09 | 2005-11-09 | Lafutidine-containing medicament composition for treating peptic ulcer |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510200680 Division CN1785429A (en) | 2005-11-09 | 2005-11-09 | A kind of medicinal composition for treating peptic ulcer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101428024A true CN101428024A (en) | 2009-05-13 |
Family
ID=40643794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008103049156A Pending CN101428024A (en) | 2005-11-09 | 2005-11-09 | Lafutidine-containing medicament composition for treating peptic ulcer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101428024A (en) |
-
2005
- 2005-11-09 CN CNA2008103049156A patent/CN101428024A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2315261C (en) | Oral pharmaceutical extended release dosage form | |
| US9636306B2 (en) | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient | |
| AU2003267924C1 (en) | Gastric acid secretion inhibiting composition | |
| KR102146395B1 (en) | Pharmaceutical formulation comprising esomeprazole and sodium bicarbonate having improved drug release properties | |
| CN108135915B (en) | tablet | |
| KR20070083956A (en) | New Modified Release Tablet Formulations for Proton Pump Inhibitors | |
| CN114901262A (en) | Oral preparation of X842 | |
| CA2347981C (en) | Process for the manufacturing of alkaline salts of substituted sulphinyl compounds and products prepared thereby | |
| KR20040079906A (en) | Tableted Oral Pharmaceutical Dosage Form, with Enteric Coating, containing A Benzimidazole compound labile in an acid medium | |
| WO2001003707A1 (en) | Heartburn treatment | |
| CN101138563A (en) | Pharmaceutical composition for treating peptic ulcer | |
| US20090280175A1 (en) | Multilayer Proton Pump Inhibitor Tablets | |
| US20090280173A1 (en) | Multilayer Omeprazole Tablets | |
| CN114224861B (en) | Enteric-coated tablets of sodium anastrozole and preparation method thereof | |
| CN101428024A (en) | Lafutidine-containing medicament composition for treating peptic ulcer | |
| CN101428018A (en) | Furanzolidon-containing medicament composition for treating peptic ulcer | |
| CN101428022A (en) | Pantoprazole-containing medicament composition for treating peptic ulcer | |
| CN101428019A (en) | Famotidine-containing medicament composition for treating peptic ulcer | |
| CN101428017A (en) | Tainuolacuo-containing medicament composition for treating peptic ulcer | |
| CN101428023A (en) | Medicament composition for treating peptic ulcer | |
| KR20210012881A (en) | Pharmaceutical formulation comprising esomeprazole and sodium bicarbonate having improved drug release properties | |
| CN1814289A (en) | Pharmaceutical composition for treating peptic ulcer | |
| CN101524336B (en) | Dosage forms for oral administration of magnesium salt of pantoprazole | |
| CN1814291A (en) | Medicine composition for preventing and treating degestive ulcer | |
| CN101269037A (en) | Esomeprazole magnesium sustained-release dropping pill and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090513 |